Search
for
Sort by
Research 31–60 of 1000+
- Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
- Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
- Finasteride prescribed for hair loss consistently leads to depression. Comment on ‘Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement’
- Two cases of stroke associated with the use of finasteride，an approved drug for male-pattern hair loss in Japan
- Hair Loss in a Hemodialysis Patient after Repetitive Use of the Antipruritic Drug Nalfurafine: Implications of Impaired Angiogenesis for Hair Loss
- MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
- A proposed etiopathology of persistent dysfunctions emerging from use and discontinuation of 5-alpha reductase inhibitors: sequelae of drug-mediated microvasculopathy
- Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
- A Systematic Review and Meta-analysis of Randomized Controlled Trials of United States Food and Drug Administration-Approved, Home-use, Low-Level Light/Laser Therapy Devices for Pattern Hair Loss: Device Design and Technology.
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use
- ANALYSIS OF THE BACKGROUND LEVEL OF CYTOKINES M1 AND M2 OF THE MACROPHAGE PHENOTYPE IN PATIENTS WITH REVISION RHINOPLASTY AFTER THE USE OF THE DRUG PDRN
- Computational Drug Discovery in Chemotherapy-induced Alopecia via Text Mining and Biomedical Databases
- Cutaneous manifestations associated with substance use disorders
- Incidence of adverse cutaneous drug reactions in a Mexican sample: an exploratory study on their association to tumour necrosis factor alpha TNF2 allele
- Use of human induced pluripotent stem cell-derived CD271+CD90+ mesenchymal stem cells for the generation of hair inductive dermal cells
- Hair loss due to methylphenidate use: A case study
- Nail Hyperpigmentation Following Valproic Acid Use: A Rare Case Report
- Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy
- Use of Minoxidil Sulfate versus Minoxidil Base in Androgenetic Alopecia Treatment: Friend or Foe?
- Recent Advances in Biodegradable and Biocompatible Synthetic Polymers Used in Skin Wound Healing
- Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
- Alopecia associated with agomelatine use: a case report
- Medicinal and cosmetic products used in treatment of hair loss
- Hair Loss Therapeutics Drug Database
- Hair Loss Therapeutics Drug Database
- Hair repigmentation associated with the use of brentuximab
- Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
- Prospects for the use of physiotherapy methods in the treatment of telogen alopecia